Horizon Pharma shares offer 'significant value,' says Stifel Stifel sees "significant value" in shares of Horizon Pharma with today's pullback and it keeps a Buy rating on the name. The firm says Express Scripts and Caremark putting Duexis and Vimovo on their exclusion lists is a "large disappointment," but it believes management has several avenues to offset the impact. Stifel lowered its price target for shares to $20 from $25.
News For HZNP From The Last 14 Days
Check below for free stories on HZNP the last two weeks.